Could High-Dose testosterone boost chemo against Hard-to-Treat prostate cancer?
NCT ID NCT06039371
First seen Jan 16, 2026 · Last updated Jun 22, 2026 · Updated 29 times
Summary
This phase 2 trial tests whether giving high levels of testosterone alongside chemotherapy (carboplatin or etoposide) or a targeted radioactive drug (LuPSMA) can shrink tumors in men with advanced prostate cancer that has stopped responding to hormone therapy. The study will enroll 69 participants and measure how many have a significant drop in PSA levels. The goal is to find a new way to treat this aggressive form of prostate cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IVB PROSTATE CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fred Hutch/University of Washington Cancer Consortium
RECRUITINGSeattle, Washington, 98109, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
testosterone, carboplatin, etoposide, lutetium Lu-177 PSMA-617
What this could lead to
If it works, this could offer a new treatment option for men with advanced prostate cancer that has stopped responding to standard hormone therapy.
What could go wrong
This is a small, early-phase trial (69 people) and the combination may cause significant side effects. It is not yet known if it will improve survival or quality of life.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.